Reach more patients faster with our decentralised clinical trial services

Schedule a consultation

Overcoming traditional trial barriers

Bringing a new therapy to market is expensive, complex and time-sensitive. Traditional site-based trials can slow progress with limited patient reach, high dropout rates and rising operational costs.

By partnering with Sciensus, biopharma companies gain the confidence of working with an established provider that helps deliver studies faster, at scale and with better patient outcomes.

Enhance your clinical program by finding and engaging patients where they are

Accelerated recruitment and retention

Engage a wider, more diverse patient population and reduce dropouts with convenient home and remote trial options.

Improved data quality

Capture real-time insights through digital platforms and nurse-led patient monitoring.

Comprehensive European network

Cost efficiency and scalability

Reduce site-related costs while expanding trial reach across multiple geographies.

Enhance and accelerate reach of your clinical trials

Sciensus delivers a fully integrated DCT service as all our staff have GCP training. From home-based patient care by Sciensus nurses and secure IMP holding and distribution to regulatory-compliant trial management. Our approach ensures every patient receives treatment safely, on time and with minimal disruption to their daily lives. We also capture all this evidence in ready to use formats.

Our decentralised clinical trial approach

  • Home and remote patient visits

    Trained clinical trial nurses administer IMPs, collect samples and monitor patient safety at home.

  • Digital patient engagement

    Secure platforms support remote consent, adherence monitoring and real-time data collection.

  • Specialist pharmacy and logistics

    GDP-compliant supply chain covering ambient to -90°C, integrated pharmacy services and resilient European distribution.

    Turn dropout challenges into retention success

    Get in touch to see how integrated homecare, digital tools and specialist logistics keep patients engaged.

    Schedule a consultation

    Sciensus is a leader in decentralised clinical trial services across Europe, supporting Phase II–IV studies, insight research and early access schemes. Our unique model combines home-based nursing care, advanced digital platforms and specialist pharmacy services to create a seamless patient and sponsor experience.

    With our GDP-compliant distribution network and expertise in handling IMPs at all temperature ranges, we enable safe and efficient trial execution. Our integrated solutions ensure regulatory compliance, enhance data integrity and reduce operational complexity.

    By partnering with Sciensus, pharma and biotech companies gain the confidence of working with an established provider that helps deliver studies faster, at scale and with better patient outcomes.

    Why partner with Sciensus?

    Improved retention through improved patient experience

    Expert clinical care and customised patient support allow us to achieve 90%+ retention rates in many of our studies.

    Customisable end-to-end clinical solutions

    Tailored trial models integrate homecare, digital technology and regulatory compliance to accelerate and enhance the output of your clinical studies.

    Time-proven European network

    Trusted partnerships with 50+ pharma companies, 180 NHS Trusts and 4,000+ healthcare providers.

    Frequently asked questions

    Are decentralised clinical trials used in the UK?

    Yes, decentralised clinical trials are increasingly common in the UK and Europe. Sciensus’ established trial network ensures seamless execution across multiple geographies.

    How does Sciensus support decentralised clinical trials?

    We provide end-to-end solutions, including home nurse visits, IMP logistics, digital consent platforms, regulatory compliance and real-world data collection.

    What are the advantages of direct-to-patient clinical trials?

    They remove barriers to participation, improve recruitment of diverse populations and reduce dropout rates by minimising patient travel.

    Can Sciensus customise a DCT solution for my study?

    Yes, our services are fully customisable to your study’s size, scope and therapeutic area. We tailor trial models to meet sponsor, patient and regulatory requirements.

    Meet our clinical trials expert

    Chris Appleby

    Director of Oncology Services

    Chris Appleby joined Sciensus in 2011 as a Cancer Pharmacist, following four years in the NHS. He led the Cancer Pharmacy, overseeing compounding and clinical trials, before serving as Chief Pharmacist for six years. During this time, he helped establish our Medical Advisory Committee and led the construction of our aseptic compounding unit.

    In 2022, Chris became Business Development Director – Specialist Services, focusing on new propositions such as clinical trials and direct-to-hospital compounding. His initiatives include developing Sciensus’ commercial compounding services, collaborating with hospitals and expanding our portfolio. Chris has also completed an MBA and continues to drive growth in cancer care and specialised patient pathways.

    Connect with Chris

     

    Get in touch

    Thank you for your interest in Sciensus. Whether you’re seeking information, partnership opportunities, or want to refer a patient, our dedicated team is here to assist you. Please fill out the form on the right, and one of our multi-lingual representatives will get in touch with you promptly.

    This field is for validation purposes and should be left unchanged.
    Please let us know details of your enquiry so that we can support you.
    Service of interest
    Click all that apply
    Consent(Required)